Knab Amy M, Shanely R Andrew, Henson Dru A, Jin Fuxia, Heinz Serena A, Austin Melanie D, Nieman David C
Appalachian State University, Kannapolis, NC, USA.
J Am Diet Assoc. 2011 Apr;111(4):542-9. doi: 10.1016/j.jada.2011.01.013.
In vitro data indicate quercetin has antioxidative and anti-inflammatory functions with the potential to lower disease risk factors, but data in human beings are limited.
The objective of this study was to investigate the effect of quercetin, vitamin C, and niacin supplements (500 mg quercetin, 125 mg vitamin C, and 5 mg niacin [Q-500]; 1,000 mg quercetin, 250 mg vitamin C, and 10 mg niacin [Q-1,000]), on disease risk factors in a large group of community adults (n=1,002, 60% women) varying widely in age and body mass index.
Subjects were randomized into one of three groups (placebo, Q-500, or Q-1,000) and ingested supplements for 12 weeks. Blood samples were taken pre- and postsupplementation, and plasma quercetin, inflammatory markers (ie, C-reactive protein and five cytokines), diagnostic blood chemistries, blood pressure, and blood lipid profiles were measured.
Plasma quercetin increased in the Q-500 and Q-1,000 groups. No differences in blood chemistries were found except for a small decrease in serum creatinine and increase in glomerular filtration rate in Q-500 and Q-1,000 groups. A small decrease in mean arterial blood pressure was measured for Q-500 and Q-1,000 groups compared to placebo. A difference in serum total cholesterol was measured between Q-500 and placebo groups, and there was small decrease in high-density lipoprotein cholesterol levels in the Q-1,000 group. Change in inflammatory measures did not differ between groups except for a slight decrease in interleukin-6 for the Q-1,000 group.
Q-500 or Q-1,000 supplementation for 12 weeks had a negligible influence on disease risk factors.
体外实验数据表明,槲皮素具有抗氧化和抗炎功能,有可能降低疾病风险因素,但人体研究数据有限。
本研究旨在调查槲皮素、维生素C和烟酸补充剂(500毫克槲皮素、125毫克维生素C和5毫克烟酸[Q-500];1000毫克槲皮素、250毫克维生素C和10毫克烟酸[Q-1000])对一大群年龄和体重指数差异很大的社区成年人(n = 1002,60%为女性)疾病风险因素的影响。
受试者被随机分为三组(安慰剂组、Q-500组或Q-1000组)之一,并摄入补充剂12周。在补充剂摄入前后采集血样,测量血浆槲皮素、炎症标志物(即C反应蛋白和五种细胞因子)、诊断性血液化学指标、血压和血脂谱。
Q-500组和Q-1000组的血浆槲皮素增加。除Q-500组和Q-1000组血清肌酐略有下降和肾小球滤过率略有增加外,血液化学指标未发现差异。与安慰剂组相比,Q-500组和Q-1000组的平均动脉血压略有下降。Q-500组和安慰剂组之间血清总胆固醇存在差异,Q-1000组高密度脂蛋白胆固醇水平略有下降。除Q-1000组白细胞介素-6略有下降外,各组炎症指标变化无差异。
补充Q-500或Q-1000 12周对疾病风险因素的影响可忽略不计。